Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694900 | 0.77 | ESR2 (0.37) | PDE2AALDH1A1LMNAALOX15 | |
| SCHEMBL28099025 | 0.76 | TYR (0.37) | PDE2ANR1I2ALDH1A1LMNACYP2C9 | |
| SCHEMBL29950853 | 0.75 | ALDH1A1 (0.38) | ENPP2ALDH1A1HTT | |
| SCHEMBL19617371 | 0.73 | ESR2 (0.33) | PDE2AALOX15 | |
| SCHEMBL28229893 | 0.73 | HSD17B10 (0.46) | CYP2C9HSD17B10 | |
| SCHEMBL28229195 | 0.73 | PDE2A (0.30) | PDE2A | |
| SCHEMBL26830240 | 0.73 | PDE2A (0.34) | PDE2ANR1I2ALDH1A1LMNACYP2C9 | |
| SCHEMBL29951465 | 0.71 | KIF11 (0.44) | ENPP2NR1I2ALDH1A1LMNACYP2C9 | |
| SCHEMBL29344094 | 0.69 | CYP3A4 (0.33) | ALOX15 | |
| SCHEMBL29469116 | 0.67 | ADRA2A (0.39) | ENPP2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | PDE2A 4045/4885ENPP2 3527/4885NR1I2 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.